Search

everythinglearnresearchcommunity

for

Search:↓

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Natural products can help overcome cancer drug resistance.

Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Certain natural compounds called terpenes may help prevent prostate cancer.

Higher cholesterol levels increase aggressive prostate cancer risk.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Analog 23 is a promising compound for prostate cancer treatment.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Mutations in certain receptors can cause diseases and offer new treatment options.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Low testosterone in men is a risk factor for a specific heart rhythm issue, and testosterone treatment may help prevent it.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.